Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cognetivity Neurosciences Ltd (CGN.CN)

Cognetivity Neurosciences Ltd (CGN.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,344
  • Shares Outstanding, K 89,589
  • Annual Sales, $ 45 K
  • Annual Income, $ -7,434 K
  • 60-Month Beta -0.23
  • Price/Sales 16.50
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CGN.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.03 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0150 +33.33%
on 04/22/24
0.0450 -55.56%
on 04/10/24
+0.0050 (+33.33%)
since 03/22/24
3-Month
0.0100 +100.00%
on 02/15/24
0.0450 -55.56%
on 04/10/24
unch (unch)
since 01/23/24
52-Week
0.0100 +100.00%
on 02/15/24
0.3650 -94.52%
on 04/25/23
-0.3200 (-94.12%)
since 04/21/23

Most Recent Stories

More News
CognICA(TM) Shown to Save Tens of Millions of Dollars in Healthcare Costs Annually and Improve Patient Outcomes in the UK National Health Service

Latest Peer-Reviewed Study Published in Frontiers in Public Health Highlights Cost-Efficiency and Improved Clinical Outcomes from Using Cognetivity's Proprietary CognICA(TM) Technology, Showing Savings...

CGNSF : 0.0123 (+11.82%)
CGN.CN : 0.0200 (+33.33%)
Cognetivity Neurosciences and UC Health Partner to Improve Early Detection of Cognitive Impairment in USA

Collaboration With Highly Rated Healthcare Provider Opens US Healthcare Market for Brain Health for AI Powered CognICA, Enabling Patient Access to Latest Alzheimer's DrugsVancouver, British Columbia--(Newsfile...

CGNSF : 0.0123 (+11.82%)
CGN.CN : 0.0200 (+33.33%)
Cognetivity Neurosciences Announces Commercial Agreement with Mediclinic to Provide Cognitive Assessment to Over 50s

Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated CareVancouver, British Columbia--(Newsfile Corp. - October 3, 2023) - Cognetivity...

CGNSF : 0.0123 (+11.82%)
CGN.CN : 0.0200 (+33.33%)
Cognetivity Neurosciences Partners with No Fear Counselling to Pioneer Brain Health Assessment Through Groundbreaking AI Technology

New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North AmericaVancouver, British Columbia--(Newsfile Corp. - September 21, 2023) - Cognetivity...

CGNSF : 0.0123 (+11.82%)
CGN.CN : 0.0200 (+33.33%)
Cognetivity Neurosciences' AI Powered CognICA Platform Wins Major Industry Award

CognICA Chosen as Winner of Best AI Product in Healthcare Award at CogX FestivalVancouver, British Columbia--(Newsfile Corp. - September 13, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF)...

CGNSF : 0.0123 (+11.82%)
CGN.CN : 0.0200 (+33.33%)
Cognetivity Neurosciences' AI Powered CognICA Platform Shortlisted for Major Industry Award

CognICA Shortlisted for Most Innovative AI Product in Healthcare Award at CogX FestivalVancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB:...

CGNSF : 0.0123 (+11.82%)
CGN.CN : 0.0200 (+33.33%)
Cognetivity Neurosciences Announces Publication of Peer-Reviewed Article Showing Effectiveness of its AI Powered CognICA Technology in Detecting Early-Stage Alzheimer's Disease

Cognetivity's Landmark ADePT Study, Funded by the UK Innovation Agency and Published in Leading Neuroscience Journal Demonstrates Unprecedented Sensitivity in Detecting Cognitive Impairment in Early Stage...

CGNSF : 0.0123 (+11.82%)
CGN.CN : 0.0200 (+33.33%)
Cognetivity Neurosciences Announces Successful Registration With Health Canada for Clinical use of CognICA(TM) AI-Powered Brain Health Technology in Canada

Approval opens up a new major market for CognICA, providing a solution to the urgent requirement for large-scale early detection and monitoring for the rollout of incoming Alzheimer's disease drugsVancouver,...

CGNSF : 0.0123 (+11.82%)
CGN.CN : 0.0200 (+33.33%)
New Disease Modifying Drug for Alzheimer's Disease Fully Approved by FDA, Highlighting the Crucial Role for Cognetivity in Early Detection and Monitoring

Vital breakthrough for Alzheimer's patients worldwide with Eisai's Leqembi FDA approval; Cognetivity Neurosciences' AI CognICA technology poised to play pivotal role in early detection and monitoring globallyVancouver,...

CGNSF : 0.0123 (+11.82%)
CGN.CN : 0.0200 (+33.33%)
Cognetivity Neurosciences AI Platform Technology to Play a Pivotal Role in the Effective Delivery of Newly Approved Alzheimer's Drugs

US Medicare & Medicaid to require data collection as part of drug reimbursementVancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE:1UB) ("the...

CGNSF : 0.0123 (+11.82%)
CGN.CN : 0.0200 (+33.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment...

See More

Key Turning Points

3rd Resistance Point 0.0150
2nd Resistance Point 0.0150
1st Resistance Point 0.0150
Last Price 0.0200
1st Support Level 0.0150
2nd Support Level 0.0150
3rd Support Level 0.0150

See More

52-Week High 0.3650
Fibonacci 61.8% 0.2294
Fibonacci 50% 0.1875
Fibonacci 38.2% 0.1456
Last Price 0.0200
52-Week Low 0.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar